Compare CPK & AMLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CPK | AMLX |
|---|---|---|
| Founded | 1990 | 2014 |
| Country | United States | United States |
| Employees | N/A | 136 |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 3.7B |
| IPO Year | 1995 | 2021 |
| Metric | CPK | AMLX |
|---|---|---|
| Price | $140.77 | $27.68 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 12 |
| Target Price | ★ $147.25 | $42.64 |
| AVG Volume (30 Days) | 133.4K | ★ 1.3M |
| Earning Date | 11-05-2026 | 11-05-2026 |
| Dividend Yield | ★ 2.08% | N/A |
| EPS Growth | 13.50 | ★ 65.46 |
| EPS | ★ 3.51 | N/A |
| Revenue | ★ $930,000,000.00 | $380,786,000.00 |
| Revenue This Year | $10.28 | N/A |
| Revenue Next Year | $5.10 | N/A |
| P/E Ratio | $40.37 | ★ N/A |
| Revenue Growth | 18.14 | ★ 1612.94 |
| 52 Week Low | $118.88 | $10.83 |
| 52 Week High | $142.26 | $41.14 |
| Indicator | CPK | AMLX |
|---|---|---|
| Relative Strength Index (RSI) | 71.75 | 54.29 |
| Support Level | $120.53 | $26.16 |
| Resistance Level | N/A | $34.35 |
| Average True Range (ATR) | 2.63 | 1.48 |
| MACD | 0.97 | 0.28 |
| Stochastic Oscillator | 95.89 | 70.80 |
Chesapeake Utilities Corp is an energy delivery company engaged in the distribution of natural gas, electricity, and propane; the transmission of natural gas; the generation of electricity and steam; and providing mobile compressed natural gas and other energy-related services to its customers. The company operates in two reportable segments, Regulated Energy and Unregulated Energy. The company's natural gas and electric distribution operations in Delaware, Maryland, and Florida are subject to regulation by PSC. Eastern Shore's natural gas transmission is subject to regulation by the FERC, and Peninsula Pipeline and Aspire Energy Express, its intrastate pipeline subsidiaries, are subject to regulation by the Florida PSC and Public Utilities Commission of Ohio, respectively.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.